Product Description
Human Breast Cancer Stem Cell - T75 Plated Cells
Also Avaliable as:
Frozen Vial Cells shipped with Dry-ice. Cat#36102-29
T25 plated Cells shipped at room temperature. Cat#36102-29-T25
120 Population doublings or up to 12 passages.
This product would require pre-coated flasks with Human Breast Cancer Stem Cell Extra-cellular Matrix Cat# E36102-29 and Human Breast Cancer Stem Cell Media Cat# M36102-29
Cell Cultures from single donors, 1000 different cell cultures available, please indicate which lots you require from the 1000 donors, or any subcategories of the cancer type at the time of order. If you do not specify the subcategory, we will provide you the Human Breast CSC, randomly from our inventory.
Source: Human Breast Cancer tissue (Triple Negative: ER, PR and Her 2 Negative)
Positive Markers: CD133, CD44, SSEA3/4, Oct4, Tumorigenicity (<1000 cells), Alkaline Phosphatase, Aldehyde Dehydrogenase, Telomerase
For non-academic use, please inquire for pricing.
Cells are only guaranteed with purchase of Celprogen Media and Celprogen Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.
ELISA Characterization Kits:
CD44 - Human Breast CSC Characterization Kit - Cat# K36102-29A
Nestin - Human Breast CSC Characterization Kit - Cat# K36102-29B
Oct 3/4 - Human Breast CSC Characterization Kit - Cat# K36102-29C
SSEA 3/4 - Human Breast CSC Characterization Kit - Cat# K36102-29D
CD133 - Human Breast CSC Characterization Kit - Cat# K36102-29-E
Publications:
Cancer Stem Cells being utilized in Cell-based assay screening
in the development of Novel Anti-Cancer Drug Candidates for organ-specific tumor therapy...
View Publication
Celprogen Launches Human Triple Negative Breast Cancer Stem Cells - Publication by Genetic Engineering & Biotechnology News
View Press Release
1000 individual donors are fully characterized proprietary patient-derived xenografts (PDX) representing all major histotypes and capturing tumor diversity.
Subcutaneous, orthotopic and disseminated models. Extensive molecular and pharmacological characterization as well as information on patients' pretreatment to help you select the most appropriate model.
Integrated approach: use the same PDX models and/or the corresponding cell line in 2D/3D screening assays and follow-up in vivo studies, identify biomarkers predicting tumor sensitivity for your compound.
Individually tailored study designs: proof of concept, dose level and schedule optimization, combinations, biomarker identification, etc.
Publication
